BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

23693

544172

INDGN

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

INDEGENE LIMITED performance

Today’s low

Today’s high

₹ 545.25 ₹ 569.00
₹ 547.75

52 week low

52 week high

₹ 470.10 ₹ 736.30
₹ 547.75

Open Price

₹ 560.40

Prev. Close

₹ 558.10

Volume (Shares)

366738.00

Total traded value

₹ 2008.80

Upper Circuit

₹ 669.70

Lower Circuit

₹ 446.50

info

INDEGENE LIMITED Share Price Update

As of the latest trading session, INDEGENE LIMITED share price is currently at ₹ 547.75, which is down by ₹ -10.34 from its previous closing. Today, the stock has fluctuated between ₹ 545.25 and ₹ 569.00. Over the past year, INDEGENE LIMITED has achieved a return of -2.24 %. In the last month alone, the return has been -3.07 %. Read More...

INDEGENE LIMITED fundamentals


  • Market cap (Cr)

    12,163.47

  • P/E Ratio (TTM)

    73.91

  • Beta

    0.94

  • Book Value / share

    78.67

  • Return on equity

    15.77%

  • EPS (TTM)

    7.55

  • Dividend yield

    0.36%

  • Net profit/quarter (Cr)

    54.20

info icon alternate text
  • Market cap (Cr)

    12,203.44

  • P/E Ratio (TTM)

    73.91

  • Beta

    0.90

  • Book Value / share

    78.67

  • Return on equity

    15.77%

  • EPS (TTM)

    7.55

  • Dividend yield

    0.36%

  • Net profit/quarter (Cr)

    54.20

info icon alternate text

INDEGENE LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 266.70
Operating Expense 235.50
Net Profit 54.20
Net Profit Margin (%) 20.32
Earnings Per Share (EPS) 2.26
EBITDA 74.80
Effective Tax Rate (%) 18.37
Particulars DEC 2024 (Values in Cr)
Revenue 286.70
Operating Expense 242.90
Net Profit 49.90
Net Profit Margin (%) 17.40
Earnings Per Share (EPS) 2.09
EBITDA 74.19
Effective Tax Rate (%) 24.50
Particulars SEP 2024 (Values in Cr)
Revenue 281.70
Operating Expense 243.10
Net Profit 44.80
Net Profit Margin (%) 15.90
Earnings Per Share (EPS) 1.88
EBITDA 68.80
Effective Tax Rate (%) 26.55
Particulars JUN 2024 (Values in Cr)
Revenue 258.60
Operating Expense 227.20
Net Profit 32.60
Net Profit Margin (%) 12.60
Earnings Per Share (EPS) 1.41
EBITDA 53.20
Effective Tax Rate (%) 27.71
Particulars MAR 2024 (Values in Cr)
Revenue 272.50
Operating Expense 235.20
Net Profit 48.90
Net Profit Margin (%) 17.94
Earnings Per Share (EPS) 2.20
EBITDA 69.50
Effective Tax Rate (%) 19.03
Particulars MAR 2025 (Values in Cr)
Revenue 1093.60
Operating Expense 945.50
Net Profit 181.30
Net Profit Margin (%) 16.57
Earnings Per Share (EPS) 7.64
EBITDA 270.90
Effective Tax Rate (%) 23.98
Particulars MAR 2024 (Values in Cr)
Revenue 1045.60
Operating Expense 915.30
Net Profit 137.90
Net Profit Margin (%) 13.18
Earnings Per Share (EPS) 6.22
EBITDA 218.29
Effective Tax Rate (%) 23.64
Particulars MAR 2023 (Values in Cr)
Revenue 1005.70
Operating Expense 865.90
Net Profit 130.20
Net Profit Margin (%) 12.94
Earnings Per Share (EPS) 5.89
EBITDA 214.70
Effective Tax Rate (%) 26.27
Particulars MAR 2022 (Values in Cr)
Revenue 836.70
Operating Expense 694.60
Net Profit 132.70
Net Profit Margin (%) 15.85
Earnings Per Share (EPS) 758.28
EBITDA 196.50
Effective Tax Rate (%) 21.89
Particulars MAR 2021 (Values in Cr)
Revenue 511.00
Operating Expense 381.71
Net Profit 133.39
Net Profit Margin (%) 26.10
Earnings Per Share (EPS) 850.00
EBITDA 177.48
Effective Tax Rate (%) 17.39
Particulars MAR 2024 (Values in Cr)
Book Value / Share 64.37
ROE % 27.01
ROCE % 27.00
Total Debt to Total Equity 0.40
EBITDA Margin 22.56
Particulars MAR 2023 (Values in Cr)
Book Value / Share 48.03
ROE % 29.12
ROCE % 29.51
Total Debt to Total Equity 0.31
EBITDA Margin 19.69
Particulars MAR 2022 (Values in Cr)
Book Value / Share 4352.71
ROE % 34.93
ROCE % 41.60
Total Debt to Total Equity 0.11
EBITDA Margin 18.79
Particulars MAR 2021 (Values in Cr)
Book Value / Share 2073.47
ROE % 133.87
ROCE % 59.18
Total Debt to Total Equity 0.41
EBITDA Margin 27.01
Particulars MAR 2020 (Values in Cr)
Book Value / Share -668.89
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.65
EBITDA Margin 22.96
Particulars MAR 2024 (Values in Cr)
Book Value / Share 42.96
ROE % 15.77
ROCE % 19.54
Total Debt to Total Equity 0.05
EBITDA Margin 20.88
Particulars MAR 2023 (Values in Cr)
Book Value / Share 35.91
ROE % 18.02
ROCE % 22.85
Total Debt to Total Equity 0.07
EBITDA Margin 21.35
Particulars MAR 2022 (Values in Cr)
Book Value / Share 3250.00
ROE % 29.36
ROCE % 34.22
Total Debt to Total Equity 0.07
EBITDA Margin 23.49
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1692.67
ROE % 96.36
ROCE % 47.72
Total Debt to Total Equity 0.12
EBITDA Margin 35.30
Particulars MAR 2020 (Values in Cr)
Book Value / Share -20.67
ROE % 67.47
ROCE % 26.30
Total Debt to Total Equity 0.14
EBITDA Margin 30.22
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 191.00
Total Assets 2545.60
Total Liabilities 2545.60
Total Equity 1429.10
Share Outstanding 222062383
Price to Book Ratio 0.00
Return on Assets (%) 13.22
Return on Capital (%) 18.38
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 85.80
Total Assets 2203.90
Total Liabilities 2203.90
Total Equity 1063.80
Share Outstanding 221475114
Price to Book Ratio 0.00
Return on Assets (%) 12.07
Return on Capital (%) 18.25
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 517.30
Total Assets 1353.46
Total Liabilities 1353.46
Total Equity 763.90
Share Outstanding 1754085
Price to Book Ratio 0.00
Return on Assets (%) 12.17
Return on Capital (%) 21.07
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 139.90
Total Assets 596.04
Total Liabilities 596.04
Total Equity 333.08
Share Outstanding 1566965
Price to Book Ratio 0.00
Return on Assets (%) 25.06
Return on Capital (%) 41.75
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 180.34
Total Assets 600.24
Total Liabilities 600.24
Total Equity -15.59
Share Outstanding 1566978
Price to Book Ratio 0.00
Return on Assets (%) -1.04
Return on Capital (%) -1.45
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 15.60
Total Assets 1220.30
Total Liabilities 1220.30
Total Equity 953.80
Share Outstanding 222062383
Price to Book Ratio 0.00
Return on Assets (%) 11.30
Return on Capital (%) 14.46
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 54.00
Total Assets 1037.70
Total Liabilities 1037.70
Total Equity 795.30
Share Outstanding 221475114
Price to Book Ratio 0.00
Return on Assets (%) 12.54
Return on Capital (%) 16.37
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 38.80
Total Assets 850.10
Total Liabilities 850.10
Total Equity 650.00
Share Outstanding 1754085
Price to Book Ratio 0.00
Return on Assets (%) 15.60
Return on Capital (%) 20.42
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 18.20
Total Assets 372.60
Total Liabilities 372.60
Total Equity 253.90
Share Outstanding 1566965
Price to Book Ratio 0.00
Return on Assets (%) 35.53
Return on Capital (%) 52.15
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 36.00
Total Assets 431.10
Total Liabilities 431.10
Total Equity -3.10
Share Outstanding 1566978
Price to Book Ratio 0.00
Return on Assets (%) 7.35
Return on Capital (%) 9.5
Particulars MAR 2024 (Values in Cr)
Net Income 458.60
Cash from Operations 632.60
Cash from Investing -327.20
Cash from Financing -66.20
Net change in Cash 114.30
Free Cash Flow 643.30
Particulars MAR 2023 (Values in Cr)
Net Income 363.00
Cash from Operations 238.40
Cash from Investing -893.30
Cash from Financing 333.10
Net change in Cash -430.00
Free Cash Flow 257.20
Particulars MAR 2022 (Values in Cr)
Net Income 226.49
Cash from Operations 367.38
Cash from Investing -160.20
Cash from Financing 233.47
Net change in Cash 370.31
Free Cash Flow 392.09
Particulars MAR 2021 (Values in Cr)
Net Income 195.84
Cash from Operations 221.64
Cash from Investing -24.24
Cash from Financing -131.50
Net change in Cash 16.27
Free Cash Flow 242.25
Particulars MAR 2020 (Values in Cr)
Net Income 15.12
Cash from Operations 49.25
Cash from Investing -18.49
Cash from Financing 136.35
Net change in Cash 140.13
Free Cash Flow 55.30
Particulars MAR 2024 (Values in Cr)
Net Income 180.60
Cash from Operations 225.50
Cash from Investing -187.70
Cash from Financing -15.80
Net change in Cash -27.30
Free Cash Flow 235.40
Particulars MAR 2023 (Values in Cr)
Net Income 176.60
Cash from Operations 123.70
Cash from Investing -47.90
Cash from Financing -16.90
Net change in Cash 17.10
Free Cash Flow 139.50
Particulars MAR 2022 (Values in Cr)
Net Income 169.90
Cash from Operations 74.10
Cash from Investing -266.70
Cash from Financing 244.90
Net change in Cash 16.40
Free Cash Flow 95.10
Particulars MAR 2021 (Values in Cr)
Net Income 159.90
Cash from Operations 78.90
Cash from Investing -33.20
Cash from Financing -37.10
Net change in Cash -17.00
Free Cash Flow 97.30
Particulars MAR 2020 (Values in Cr)
Net Income 46.50
Cash from Operations 104.60
Cash from Investing -51.40
Cash from Financing -18.50
Net change in Cash 19.70
Free Cash Flow 109.80
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6992.60 76.74 13.41 100542.86 5690.80 / 7545.10
FORTIS MALAR HOSPITALS LIMITED 78.74 192.05 4.94 147.57 51.01 / 98.70
SHREE PACETRONIX LTD. 71.00 14.79 1.90 25.56 61.11 / 268.50
TRANSGENE BIOTEK LTD. 3.75 0.00 2.62 28.41 3.22 / 10.84
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6992.60 83.66 12.27 100542.86 5690.80 / 7545.10
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 31.25 0.00 -16.74 23.34 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 5584.95 29.60 6.27 6109.94 3750.00 / 6400.00

INDEGENE LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
547.75 -1.85 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 566.70
  • 26 Days 563.30
  • 10 Days 567.40
  • 50 Days 566.90
  • 12 Days 567.00
  • 100 Days 580.20
  • 20 Days 564.40
  • 200 Days 590.20
565.82 PIVOT

First Support

546.78

First Resistance

577.13

Second Support

535.47

Second Resistance

596.17

Third Support

516.43

Third Resistance

607.48

RSI

47.95

ADX

15.32

MACD

3.67

Williams % R

-35.99

Commodity Channel Index (CCI)

-7.20

Date

2025-04-29

Week

136073.00

Same Day

197008.00

Month

126066.00

1 Year

0.95

3 Year

0.95

Over 1 Month

-3.07%

down

Over 1 Year

-2.24%

down

Over 3 Months

-10.31%

down

Over 3 Years

0.00%

down

Over 6 Months

-14.48%

down

Over 5 Years

0.00%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

INDEGENE LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
89.79%
Promoter Holdings
0.0%
FII
5.24%
DII
4.96%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Nadathur Fareast Pte Ltd 5.2700256E7 (21.96%) Public Shareholding
Ca Dawn Investments 2.4475402E7 (10.2%) Public Shareholding
Manish Gupta 2.1474076E7 (8.95%) Public Shareholding
Rajesh Bhaskaran Nair 1.7192386E7 (7.16%) Public Shareholding
Bpc Genesis Fund I Spv Ltd 1.5060223E7 (6.27%) Public Shareholding
Sanjay S Parikh 1.2008172E7 (5.0%) Public Shareholding
Bpc Genesis Fund I A Spv Ltd 7811651.0 (3.25%) Public Shareholding
Gaurav Kapoor 6266736.0 (2.61%) Public Shareholding
Vida Trustees Private Limited 5588802.0 (2.33%) Public Shareholding
Anand Kiran 5211360.0 (2.17%) Public Shareholding
Fidelity Funds - India Focus Fund 4206620.0 (1.75%) Public Shareholding
Chestnut Associates (ptc) Limited As Trustee Of N Foundation 3439800.0 (1.43%) Public Shareholding
Sycamore Philanthropy (ptc) As Trustee Of Aalamaram Foundation 3439800.0 (1.43%) Public Shareholding
Sbi Innovative Opportunities Fund 3338042.0 (1.39%) Public Shareholding
Smallcap World Fund, Inc 2867323.0 (1.19%) Public Shareholding

News

Left Arrow
Right Arrow

INDEGENE LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

INDEGENE LIMITED Share Price

Indegene Limited was incorporated as Indegene Lifesystems Private Limited' at Ahmedabad, Gujarat, as a Private Limited Company, dated October 16, 1998 at Ahmedabad. Subsequently, name of the Company was changed to Indegene Private Limited' and a fresh Certificate of Incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. Thereafter, Company converted to a Public Company with change in name to Indegene Limited' on November 17, 2022.

The Company is a global provider of solutions consisting of analytics, technology and commercial, medical, regulatory and safety services to life science and healthcare organizations. It provide digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products.

Their Enterprise Commercial Solutions (ECS) involve assisting life sciences companies with their digital marketing operations. Omnichannel Activation solutions help life sciences companies leverage a 'digital first' approach for optimizing the last-mile promotion of biopharmaceutical products and medical devices to HCPs across multiple channels. Under Enterprise Medical Solutions, the Company establish centers of excellence (CoEs) to consolidate large scale regulatory and medical operations for their clients.

Apart from these, the Company offer Enterprise Clinical Solutions and consultancy services, which help drive efficiencies in the drug discovery and clinical trial operations of life sciences companies. It bring in their expertise in data management and analytics
in helping biopharmaceutical companies seamlessly handle and analyze multiple sources of data during clinical trials and build a case for regulatory approvals.

In 2016, the Company acquired Encima Group, Inc. in the United States, a company which provided marketing analytics and campaign execution solutions to several large life sciences companies.

In 2019, it acquired a minority stake in DT Associates Research and Consulting Services Limited, a digital transformation and client experience consulting firm in UK, to expand their strategic consulting capabilities. In December 2020, it acquired a majority stake in DT Associates Limited.

On 8 December, 2021 the Company has demerged its commercial software business pursuant to a Scheme of Arrangement for transfer of the Demerged Business to OT Services India Private Limited (Resulting Company), approved by the National Company Law Tribunal, Bengaluru Bench with Appointed Date, i.e., October 1, 2020, which became effective on December 30, 2021.

The Company acquired Cult Health, a full-service healthcare marketing agency for several life sciences brands, through its subsidiary, ILSL Holdings, Inc. on October 12, 2022.

The Company launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform in 2023.

The Company made a public issue of 40,766,550 Equity Shares of face value of Rs 2 each by raising funds aggregating to Rs. 1842 Crore comprising a fresh issue of 16,833,818 Equity Shares aggregating to Rs. 760 Crore and 23,932,732 Equity Shares aggregating to Rs 1082 Crore through Offer for Sale in May, 2024.

In 2024, the Company acquired a controlling stake in Trilogy Writing & Consulting GmbH.

Parent organization Indian Private
NSE symbol INDGN
Founded 1998
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Indegene Ltd?

Answer Field

The share price of Indegene Ltd for NSE is ₹ 547.75 and for BSE is ₹ 549.55.

What is the Market Cap of Indegene Ltd?

Answer Field

The market cap of Indegene Ltd for NSE is ₹ 1,21,63.47 Cr. and for BSE is ₹ 1,22,03.44 Cr. as of now.

What is the 52 Week High and Low of Indegene Ltd?

Answer Field

The 52 Week High and Low of Indegene Ltd for NSE is ₹ 736.30 and ₹ 470.10 and for BSE is ₹ 736.60 and ₹ 468.90.

How to Buy Indegene Ltd share?

Answer Field

You can trade in Indegene Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Indegene Ltd?

Answer Field

The 1 year returns on the stock has been -2.24%.

What is the Current Share Price of Indegene Ltd?

Answer Field

Indegene Ltd share price is for NSE ₹ 547.75 & for BSE ₹ 549.55 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Indegene Ltd Share?

Answer Field

The market cap of Indegene Ltd for NSE ₹ 1,21,63.47 & for BSE ₹ 1,22,03.44 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Indegene Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Indegene Ltd share is 73.91.

What is the PB ratio of Indegene Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Indegene Ltd share is 78.67.

How to Buy Indegene Ltd Share?

Answer Field

You can trade in Indegene Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Indegene Ltd Share on Bajaj Broking App?

Answer Field

To buy Indegene Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Indegene Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|